Home
OLMA
OLMA News

Latest Olema Pharmaceuticals Inc. (OLMA) News on October 29, 2025

MT Newswires

9 days ago

Olema Pharmaceuticals Shares Fall After Roche's Breast Cancer Data Weighs on Sector

MT Newswires

9 days ago

Wall Street Set to Open Higher Monday as Investors Look Ahead to a Week of Earnings Reports

MT Newswires

9 days ago

Top Premarket Decliners

MT Newswires

9 days ago

Investors Look Ahead to Key Earnings Reports as US Futures Rise Monday Pre-Bell

Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

GlobeNewswire

11 days ago

Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential

Insider Monkey

12 days ago

Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a month ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ulta Stock Jumps as Beauty Product Spending Continues

Investopedia

5 months ago

Ulta Stock Jumps as Beauty Product Spending Continues

Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy

GlobeNewswire

5 months ago

Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy

Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy

GlobeNewswire

5 months ago

Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy

Northrop Grumman Raises $1 Billion Via Debt

Benzinga

5 months ago

Northrop Grumman Raises $1 Billion Via Debt

The York Water Company Files a Rate Request Based on $145 Million in Investment

GlobeNewswire

5 months ago

The York Water Company Files a Rate Request Based on $145 Million in Investment

TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast

GlobeNewswire

5 months ago

TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast

Newsfile

5 months ago

Max Resource Corp. Announces Participation in THE Mining Investment Event, Quebec City, June 3-5, 2025

Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy

GlobeNewswire

5 months ago

Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

GlobeNewswire

5 months ago

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

Olema Oncology to Participate in Upcoming Investor Conferences

GlobeNewswire

5 months ago

Olema Oncology to Participate in Upcoming Investor Conferences

Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High?

Zacks

5 months ago

Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High?

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Simply Wall St.

5 months ago

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

MT Newswires

5 months ago

Oppenheimer Adjusts Olema Pharmaceuticals Price Target to $22 From $25, Maintains Outperform Rating

Olema Oncology Reports First Quarter 2025 Financial and Operating Results

GlobeNewswire

6 months ago

Olema Oncology Reports First Quarter 2025 Financial and Operating Results

Olema Oncology to Participate in Upcoming Investor Conferences

GlobeNewswire

6 months ago

Olema Oncology to Participate in Upcoming Investor Conferences

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

6 months ago

Top Premarket Decliners

MT Newswires

6 months ago

Olema Pharmaceuticals Says OP-3136 Molecule Shows Anti-Tumor Activity in Preclinical Models

Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

GlobeNewswire

6 months ago

Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet

Zacks

6 months ago

Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet

After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA)

Zacks

7 months ago

After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA)

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

7 months ago

Top Premarket Decliners

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

GlobeNewswire

7 months ago

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

MT Newswires

7 months ago

Olema Pharmaceuticals Q4 Net Loss Widens

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

GlobeNewswire

7 months ago

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire

8 months ago

Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary

GlobeNewswire

8 months ago

Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

9 months ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology to Participate in Upcoming Investor Conferences

GlobeNewswire

9 months ago

Olema Oncology to Participate in Upcoming Investor Conferences

MT Newswires

10 months ago

Top Midday Decliners

MT Newswires

10 months ago

Olema Pharmaceuticals Files Shelf for 2 Equity Offerings

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

10 months ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

10 months ago

Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

GlobeNewswire

a year ago

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

MT Newswires

a year ago

Olema Pharmaceuticals Cleared to Begin Testing Prospective Breast Cancer Candidate

Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

GlobeNewswire

a year ago

Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

Zacks

a year ago

Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

Novartis and Olema expand alliance with $250m to boost breast cancer trials

Pharmaceutical Technology

a year ago

Novartis and Olema expand alliance with $250m to boost breast cancer trials

MT Newswires

a year ago

Olema Partners With Novartis for Clinical Trial of Potential Breast Cancer Drug, Launches $250 Million Stock, Warrant Placement

Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement

GlobeNewswire

a year ago

Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

GlobeNewswire

a year ago

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

PR Newswire

a year ago

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Olema Oncology to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Olema Oncology to Participate in Upcoming Investor Conferences

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Simply Wall St.

a year ago

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

GlobeNewswire

a year ago

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

GlobeNewswire

a year ago

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

GlobeNewswire

a year ago

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Recent Price Trend in Olema Pharmaceuticals (OLMA) is Your Friend, Here's Why

Zacks

a year ago

Recent Price Trend in Olema Pharmaceuticals (OLMA) is Your Friend, Here's Why

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TruBridge, Evans Bancorp, and More Stocks See Action From Activist Investors

Barrons.com

a year ago

TruBridge, Evans Bancorp, and More Stocks See Action From Activist Investors

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology to Participate in Upcoming Investor Conferences in June

GlobeNewswire

a year ago

Olema Oncology to Participate in Upcoming Investor Conferences in June

Olema Pharmaceuticals (NASDAQ:OLMA) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

a year ago

Olema Pharmaceuticals (NASDAQ:OLMA) Is In A Good Position To Deliver On Growth Plans

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

GlobeNewswire

a year ago

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress

GlobeNewswire

a year ago

Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology to Participate in Upcoming Investor Conferences in May

GlobeNewswire

a year ago

Olema Oncology to Participate in Upcoming Investor Conferences in May

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

GlobeNewswire

2 years ago

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy’ Stocks

TipRanks

2 years ago

Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy’ Stocks

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 years ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire

2 years ago

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

GlobeNewswire

2 years ago

Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 years ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Calculating The Intrinsic Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Simply Wall St.

2 years ago

Calculating The Intrinsic Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Olema Oncology to Participate in Upcoming Investor Conferences

GlobeNewswire

2 years ago

Olema Oncology to Participate in Upcoming Investor Conferences

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 years ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Associated Press Finance

2 years ago

Deluxe: Q4 Earnings Snapshot

The First Bancshares, Inc. (NASDAQ:FBMS) Q4 2023 Earnings Call Transcript

Insider Monkey

2 years ago

The First Bancshares, Inc. (NASDAQ:FBMS) Q4 2023 Earnings Call Transcript

Teekay Corporation (NYSE:TK) is a favorite amongst institutional investors who own 86%

Simply Wall St.

2 years ago

Teekay Corporation (NYSE:TK) is a favorite amongst institutional investors who own 86%

Isabeau Levito edges Amber Glenn in figure skating nationals short program

NBC Sports

2 years ago

Isabeau Levito edges Amber Glenn in figure skating nationals short program

Tuya Smart Delivers IoT Best Practice Using Amazon Aurora, Leads the Direction of Cloud Database Innovation Use Cases with Amazon Web Services

PR Newswire

2 years ago

Tuya Smart Delivers IoT Best Practice Using Amazon Aurora, Leads the Direction of Cloud Database Innovation Use Cases with Amazon Web Services

Autolus Therapeutics announces publication in ACS Chemical Biology

GlobeNewswire

2 years ago

Autolus Therapeutics announces publication in ACS Chemical Biology

15 Small-Cap Stocks with High Potential

Insider Monkey

2 years ago

15 Small-Cap Stocks with High Potential

Unpacking Q3 Earnings: BJ's (NASDAQ:BJRI) In The Context Of Other Sit-Down Dining Stocks

StockStory

2 years ago

Unpacking Q3 Earnings: BJ's (NASDAQ:BJRI) In The Context Of Other Sit-Down Dining Stocks

Global Blue Announces Date for Q3 and 9M FY 2023/24 Financial Results

Business Wire

2 years ago

Global Blue Announces Date for Q3 and 9M FY 2023/24 Financial Results

Sit-Down Dining Stocks Q3 In Review: Texas Roadhouse (NASDAQ:TXRH) Vs Peers

StockStory

2 years ago

Sit-Down Dining Stocks Q3 In Review: Texas Roadhouse (NASDAQ:TXRH) Vs Peers

Specialty Retail Stocks Q3 Recap: Benchmarking Tractor Supply (NASDAQ:TSCO)

StockStory

2 years ago

Specialty Retail Stocks Q3 Recap: Benchmarking Tractor Supply (NASDAQ:TSCO)

Associated Press Finance

2 years ago

OceanFirst: Q4 Earnings Snapshot

OceanFirst Financial Corp. Announces Quarterly and Annual Earnings and Financial Results

GlobeNewswire

2 years ago

OceanFirst Financial Corp. Announces Quarterly and Annual Earnings and Financial Results

Leslie’s, Inc. to Report First Quarter Fiscal 2024 Financial Results on February 1, 2024

GlobeNewswire

2 years ago

Leslie’s, Inc. to Report First Quarter Fiscal 2024 Financial Results on February 1, 2024

3 Stocks to Buy for Growth and Stability

Zacks

2 years ago

3 Stocks to Buy for Growth and Stability

We Ran A Stock Scan For Earnings Growth And Orion (NYSE:OEC) Passed With Ease

Simply Wall St.

2 years ago

We Ran A Stock Scan For Earnings Growth And Orion (NYSE:OEC) Passed With Ease

Cohen & Steers Announces Retirement of William Scapell, Head of Fixed Income and Preferred Securities, Effective August 1, 2024

PR Newswire

2 years ago

Cohen & Steers Announces Retirement of William Scapell, Head of Fixed Income and Preferred Securities, Effective August 1, 2024

Share on Social Networks: